Robert Hsu MD (@md_hsu) profile picture

Thoracic/head and neck oncology at @uscnorris. Amateur runner (ig: travelrunnerrob) Opinions are my own.

Joined June 2022
Robert Hsu MD retweeted
Example of why having multiple agents is helpful. Series @JCOPO_ASCO of 12 pts with EGFR mutant NSCLC who switched to lazertinib due to osimertinib toxicity (pulmonary, cardiac, heme). Both 3G TKIs with similar efficacy but different toxicity profiles. ascopubs.org/doi/10.1200/PO-…
2
12
51
3,513
Robert Hsu MD retweeted
MTAP IHC (@CCR_AACR): 243 NSCLCs, 72% driver+ ➡️ MTAP loss 17%; early 13%, metastatic 20% ➡️ Stage 4: driver+ 24% vs driver- 14% (p=0.314) ➡️ PRMT5i + TKI > PRMT5i alone in MTAP-del lines PRMT5i + TKI trials next? doi.org/10.1158/1078-0432.CC… @LungCancerRx @OncoAlert @oncodaily
5
15
1,175
Robert Hsu MD retweeted
1/8 🧵 Ami just got FDA accelerated approval in R/M HNSCC after platinum + anti-PD-(L)1, excluding HPV-associated oropharyngeal SCC. A new option for our patients, here are my #hottakes on OrigAMI-4 🔥 @COlazagasti @AnaVManana @fangdisun @AriRosenbergMD @md_hsu
1
2
7
663
🔥🚨#November is 🫁 #LungCancerAwareness Month. ⭐️Lung Cancer Awareness #SavesLives. ✅Together, WITH #Patients, we keep the #Fight against #LungCancer. ✅We have made a great #Progress but still have a long way to go. #LCAM26. 👇🏼Sharing, like every year, my: ‼️#AWARENESS #Mnemonic
🤖 Made with AI
2
20
1
51
1,811
Robert Hsu MD retweeted
Starlatamab takes a huge BiTE today out of small cell lung cancer! Amazing PFS (0.34) and OS (0.42) HR and truly manageable added tox- 50% CRS but almost uniformly gr 1/2 and near non-existent ICANS, no new safety signal w durva combo just makes this one of the most impressive SCLC trials/ cancer trials ever.. Given extreme need for better treatments for our pts w ES-SCLC, unprecedented benefit seen in DeLLphi-305 plus availability/experience with use already it is a no-brainer to incorporate into our practice as SOC maintenance therapy on Monday… well, not Mon- whenever your flight takes you back post-#ESMO26 Amazing job by @sands_jacob and Amgen/DeLLphi team- glad we had a chance to offer such a transformational trial to our pts as well at Monte/Einstein! With these extraordinary results starlatamab is likely to continue to expand into 1st line/LS-SCLC settings and lets just dream on- if we as a field have taken such a tasty first BiTE, can hardly wait for the next one! Standing ovation- well deserved! #lcsm
1
11
1
41
4,618
Robert Hsu MD retweeted
It was a pleasure moderating the lung cancer case discussion at @precisca_ in LA alongside Drs. @wallyjc, @md_hsu & Dr. Brinh Linh. 🫁 🧬 Star fellow( Dr Grant, Dr Batra and Dr Basheer) presented excellent, thought-provoking cases that sparked a multidisciplinary discussion on KRAS, HER2/ERBB2, RET-driven NSCLC, perioperative strategies, oligometastatic disease, and the evolving roles of surgery and radiation. 🎯 We also discussed practical scenarios including palliative radiation for hemoptysis and surgical pleural evaluation when effusion cytology is negative but suspicion remains high. @OncWithGrant @SylvesterCancer @GlopesMd @Latinamd @HemOncMiami – at Santa Monica, CA
5
14
1,071
Neutropenic Diet Versus Liberalized Diet in Patients With Cancer: A Systematic Review and Meta-Analysis New meta-analysis of 15 studies involving 4,320 patients with cancer found that routine neutropenic diets did not reduce major infections, pneumonia, diarrhea, or mortality compared with more liberalized diets. These findings support moving away from routine dietary restrictions for most patients, while individualizing care for high-risk populations. #Oncology #CancerCare ascopubs.org/doi/10.1200/OP-… @JCOOP_ASCO @ASCO @OncoAlert
2
36
1
75
7,287
Robert Hsu MD retweeted
Trust-uzumab deruxtecan delivers for pts w ErbB2 mutated NSCLC with a RR of 70% and median PFS of 14 months beating chemo/IO easily in DESTINY Lung04 BUT- no real trends for OS benefit and concerning rate of AEs- esp 20% risk of ILD are worrisome. With that and availability of very well tolerated and similarly active TKIs - for now the DESTINY of Tdxd appears to be in the 2nd line.. @JuliaRotow
2
6
26
1,973
Robert Hsu MD retweeted
8 year update of ADAURA at #WCLC26 from @DrRoyHerbst - with 3y of adjuvant osimertinib in EGFR mutant NSCLC, 8y OS rate 74% vs 58% with OS HR 0.53 and benefit seen across stages: stage IB HR 0.50, stage II HR 0.60, stage IIIA HR 0.49 - reaffirms standard of care.
1
45
1
95
4,108
Robert Hsu MD retweeted
Landmark, practice changing study at #WCLC26. The phase III MAVERICK study shows no improvement in OS with PCI for SCLC, across limited and extensive stages, with worse cognitive failure free survival and increased toxicity in PCI arm. The end of the PCI era.
3
91
9
194
14,804
Robert Hsu MD retweeted
Registration is open for Spotlight on Oncology! Join leading experts and 100+ oncology professionals for clinical updates, emerging therapies, case-based discussions, poster presentations, and a hosted networking reception. 📍 Renaissance Newport Beach Hotel 🔗 moasc.starchapter.com/meetin… #SpotlightOnOncology #Oncology #CancerResearch @montypal @ashkanlashkari @hoperugo @mar_nataliya @JCohenMD @Gino_K_In_USC @md_hsu @DrJZell @DrArsenOsipov #DrLeeCranmer
2
2
6
3,921
Robert Hsu MD retweeted
Characterization of EGFR mutant NSCLC transformed to SCLC (n=45) @JTOonline. 70% received EP alone, 23% had EP combo (IO/TKI). Combo PFS 7.5m vs 2.8m (many confounders). DLL3+ in 88%, B7-H3+ in 67% but prior reports show poor RR to tarlatamab. ADCs here? jtocrr.org/article/S2666-364…
2
25
1
55
7,170
Robert Hsu MD retweeted
Top-line results from randomized phase III Krascendo 1 trial shows divarasib superior to first generation KRAS G12C inhibitors with improved PFS and significant improvement in OS, meeting primary endpoint. Eagerly awaiting data presentation! globenewswire.com/news-relea…
1
9
2
65
6,078
Robert Hsu MD retweeted
New in @JThoracOncol: 📌 Compound (PACC/PACC AND PACC/classical) mutations both show enhanced sensitivity to 2nd-gen TKIs (afatinib) over osimertinib in 1L 📌 PACC pts on 1L osimertinib trended toward shorter ToT vs classical (19.5 vs 28.5 mo) 🧬 Bottom line: When you see a compound mutation with a PACC component (G719X, S768I, E709X) — even if paired with L858R or Ex19del — treat it as PACC. Consider 2nd-gen TKIs over osimertinib. ⭐️Still an area of unmet need! Novel agents like firmonertinib, silevertinib enozertinib are being studied. Great effort by @LeXiuning and team! jto.org/article/S1556-0864(2…
1
17
1
41
2,792
Robert Hsu MD retweeted
REDUSE (SAKK 96/12) at #ASCO26 (Abstr 1004, oral): can denosumab be de-escalated in bone-metastatic cancer without losing skeletal protection? In patients with breast cancer or CRPC and ≥3 bone metastases (n=1,380), denosumab every 12 weeks — after 4x monthly loading — was tested for non-inferiority vs the standard every-4-weeks schedule for symptomatic skeletal events (SSE). 📊 Primary endpoint met: stratified HR 1.02 (90% CI 0.87–1.20), median time to first SSE ~56 mo in both arms. First-and-subsequent SSE also non-inferior (HR 1.04). 🦴 Less toxicity with Q12W: hypocalcemia 30% vs 46%, ONJ 6.9% vs 8.5%. My take: same skeletal protection, fewer injections, less toxicity, lower cost — this should be the new standard of care for bone-metastatic breast & prostate cancer. IMO the biology likely extends beyond these two tumors too, though the trial only tested them. One open question: the Q12W arm still got 4x monthly loading up front — do we actually need that induction phase, or could we de-escalate from the start? Looking forward to seeing the presentation! 🔗 asco.org/abstracts-presentat… #bcsm #pcsm #BoneHealth
12
2
31
7,660
Robert Hsu MD retweeted
🧵 CROWN 7-Year Update: Lorlatinib in 1L ALK+ NSCLC: the longest PFS ever reported in advanced NSCLC keeps getting longer!!! #ASCO26 🫁 Abstracts! Presenter: @TonyMok9 Key takeaways: 👇 @ALKPositiveinc 1) 1/ 📈 Median PFS STILL not reached at 7 years. • 7-yr PFS rate: 55% (lorlatinib) vs 3% (crizotinib), HR 0.19 • 44% of pts STILL on lorlatinib vs just 3% on crizotinib
🤖 Made with AI
6
41
7
119
17,700
Robert Hsu MD retweeted
Replying to @ASCO
@ASCO #ASCO26 Plenary Session Abstracts were just released and like a parent only seeing their kid at the stage- I’m only seeing the 2 thoracic 🫁abstracts and the RAS (ON) for pancreatic cancer drug that we need for lung cancer. #lcsm ▶️ #LIBRETTO432 Adj #selpercatinib 🫁 ▶️ #HARMONI6 #ivonescimab+chemo 🫁 ▶️ #RASolute302 #Daraxonrasib for pancreatic cancer
3
9
32
1,542